Core Viewpoint - The announcement by Fosun United Health Insurance regarding the inclusion of nine medical insurance products in the commercial health insurance innovative drug directory was retracted shortly after its release, raising questions about the internal decision-making process and the implications for the health insurance market [1][2]. Group 1: Announcement and Withdrawal - Fosun United Health Insurance initially announced that nine of its medical insurance products would cover drugs listed in the newly released commercial health insurance innovative drug directory [1]. - The announcement was later deleted from their official WeChat account, with the company stating that the details of the products had not been finalized, leading to the retraction [2]. Group 2: Market Implications - The release of the commercial health insurance innovative drug directory, which includes 19 high-value innovative drugs, is seen as a potential opportunity to enhance the purchasing rate of commercial insurance [4]. - The inclusion of innovative drugs in medical insurance is expected to significantly reduce the financial burden on patients and encourage pharmaceutical companies to invest in research and development [3][5]. Group 3: Challenges and Opportunities - The main challenges for insurance companies include the lack of historical data for accurate pricing and the risk of high claims due to expensive drugs [5]. - Successful integration of innovative drugs into insurance products requires effective risk management and collaboration with pharmaceutical companies to develop precise products and services [5]. Group 4: Company Performance and Capitalization - Fosun United Health Insurance, established in 2017, has shown a trend of profitability since 2021, with net profits reported at 0.20 billion, 0.63 billion, 0.23 billion, and 0.42 billion from 2021 to 2024 [6][7]. - The company recently received approval for a capital increase of 3.1641 billion, enhancing its capital strength and solvency, which is crucial for covering innovative drugs and supporting business expansion [8].

Core Insights - The insurance industry is adjusting its product structure in anticipation of a decrease in the third-quarter insurance premium interest rates, focusing on two main areas: dividend insurance with interest rate flexibility and health insurance emphasizing protection functions [1][2] - Health insurance is experiencing faster growth compared to other insurance types, becoming a new growth curve for both life and property insurance companies [1][3] - The traditional savings-type insurance model is becoming unsustainable, prompting the industry to seek new growth drivers through deep transformation [2][4] Health Insurance Market Dynamics - Health insurance is a key intersection for life and property insurance companies, with life insurers focusing on long-term health insurance and property insurers on short-term medical insurance [3][4] - The demand for health insurance is increasing due to rising health awareness and medical costs, providing a broad market space for both life and property insurers [3][4] - Recent healthcare reforms have facilitated the rapid development of health insurance, particularly in the medical insurance sector [2][4] Financial Performance and Growth Potential - Health insurance premium income has shown steady growth, with a reported income of 4,557 billion yuan in the first four months of this year, a year-on-year increase of over 4% [4][5] - Despite the growth, the health insurance market has not yet reached the target of 1 trillion yuan in premium income by 2025, indicating a significant gap [5][6] - The market is characterized by notable disparities, with some companies experiencing rapid growth while others face declines in net profit and insurance revenue [5][6] Challenges and Shortcomings - The health insurance market faces challenges such as severe product homogeneity, insufficient collaboration with the medical system, and weak data foundations [6][7] - There is a mismatch between supply and demand, with high premiums and low coverage for essential groups, leading to a lack of effective product offerings for those in need [6][7] - The industry struggles with high claim thresholds and inadequate long-term coverage options, highlighting the need for improved service systems [6][7] Recommendations for Improvement - Data sharing and collaboration among insurance companies, healthcare providers, and regulatory bodies are crucial for accurate pricing and risk assessment in health insurance [7][8] - Establishing a health data platform and promoting cooperation between commercial insurance and basic medical insurance can enhance the development of health insurance [8][9] - Companies should focus on developing differentiated products for various demographics and enhancing their health management service systems to meet diverse market needs [9]